Maternal and Child Health — MCQs

Maternal and Child Health Indian Medical PG Practice Questions and MCQs

Question 71: Which of the following is not true of colostrum?

A. It is rich in fat. (Correct Answer)
B. It is secreted for the first few days after birth.
C. It is rich in protein and minerals.
D. It is rich in anti-infective factors.

Explanation: **Explanation** Colostrum is the first milk produced by the mammary glands immediately after delivery, typically lasting for the first **2–3 days**. It is specifically designed to meet the physiological needs of a newborn. **Why Option A is the Correct Answer (The False Statement):** Contrary to popular belief, colostrum is **low in fat** compared to mature milk. The primary purpose of colostrum is not high-calorie density through lipids, but rather immunological protection and high protein content. Mature milk, which follows transition milk, has a significantly higher fat content to support the infant's rapid weight gain. **Analysis of Other Options:** * **Option B:** Colostrum is indeed the "first milk" secreted during the initial 2–3 days postpartum before transitioning into "transition milk" (days 3–14) and finally "mature milk." * **Option C:** Colostrum is significantly **richer in proteins** (especially albumin and globulin) and **minerals** (Sodium, Potassium, Magnesium, and Zinc) than mature milk. * **Option D:** It is often called "the first vaccine." It is exceptionally rich in **Secretory IgA**, lactoferrin, and lymphocytes, providing passive immunity and protecting the newborn's gut from pathogens. **High-Yield Clinical Pearls for NEET-PG:** * **Vitamin Content:** Colostrum is rich in fat-soluble vitamins, particularly **Vitamin A**, which gives it its characteristic yellowish color. * **Laxative Effect:** It has a mild laxative effect that helps the baby pass **meconium**, preventing early-onset jaundice. * **Energy Value:** Colostrum provides approximately **58 kcal/100 ml**, whereas mature milk provides about **65-70 kcal/100 ml**. * **Total Volume:** Approximately 10–40 ml of colostrum is secreted on the first day.

Question 72: What is the failure rate of condoms with typical use?

A. 10-14 per 100 woman-years (Correct Answer)
B. 14-17 per 100 woman-years
C. 17-20 per 100 woman-years
D. 20-25 per 100 woman-years

Explanation: **Explanation:** The effectiveness of a contraceptive method is measured using the **Pearl Index**, which calculates the number of unintended pregnancies per 100 woman-years of use. For barrier methods like condoms, there is a significant difference between "perfect use" (consistent and correct) and "typical use" (reflecting real-world human error). **1. Why Option A is Correct:** According to standard public health textbooks (Park’s PSM) and WHO data, the failure rate of the male condom with **typical use is 10–14 per 100 woman-years**. This higher rate compared to perfect use (which is approximately 2–3%) is attributed to inconsistent use, incorrect application, breakage, or slippage. **2. Analysis of Incorrect Options:** * **Options B, C, and D:** These values (14–25%) overestimate the failure rate of male condoms. While some older studies or specific populations might show higher rates, the standard academic benchmark for NEET-PG remains 10–14%. Rates as high as 20–25% are more characteristic of less effective methods like the diaphragm or periodic abstinence (rhythm method) under typical use. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dual Protection:** Condoms are the only contraceptive method that provides "dual protection" against both unintended pregnancy and Sexually Transmitted Infections (STIs), including HIV. * **Ideal Use vs. Typical Use:** Always distinguish between these two in exam questions. For OCPs, typical use failure is ~7-9%, while for IUCDs (Cu-T 380A), it is much lower (~0.8%). * **NIRODH:** This is the brand name for condoms distributed free of charge under the National Family Welfare Programme in India. * **Material:** Most condoms are made of latex; however, for those with latex allergies, polyurethane condoms are an alternative (though they have a higher breakage rate).

Question 73: Who is credited with developing the Road to Health chart?

A. John Snow
B. David Morley (Correct Answer)
C. Koch
D. Henry Duncan

Explanation: **Explanation:** The **Road to Health Chart** (Growth Chart) was designed by **Dr. David Morley** in the 1960s while working in Nigeria. It is a longitudinal record of a child’s physical growth and development. The primary objective is **Growth Monitoring**, which allows for the early detection of Protein-Energy Malnutrition (PEM) and other growth faltering issues before they become clinically apparent. **Why the other options are incorrect:** * **John Snow:** Known as the "Father of Modern Epidemiology," he is famous for his work on the cholera outbreak in London (Broad Street pump) and for being a pioneer in anaesthesia. * **Robert Koch:** A founding father of Bacteriology, he discovered the causative agents of Anthrax, Cholera, and Tuberculosis (Koch’s Postulates). * **Henry Duncan:** He was the first Medical Officer of Health (MOH) in the UK (Liverpool, 1847), focusing on urban sanitation. **High-Yield Clinical Pearls for NEET-PG:** * **WHO Growth Charts (2006):** Currently used in India under the ICDS program. They are based on the "Multicentre Growth Reference Study" (MGRS) and describe how children *should* grow (prescriptive) rather than just how they *do* grow (descriptive). * **Reference Curve:** The upper line (50th percentile) represents the median for international standards. * **Danger Signal:** A **flattening or falling curve** indicates growth failure and is the earliest sign of PEM, often appearing before signs like wasting or edema. * **Color Coding:** In India, the chart uses Green (Normal), Yellow (Moderately underweight), and Orange (Severely underweight) zones.

Question 74: Which color is NOT included in the IMNCI classification for a sick child?

A. Red
B. Green
C. Yellow (Correct Answer)
D. Pink

Explanation: In the **Integrated Management of Neonatal and Childhood Illness (IMNCI)** strategy, a color-coded triage system is used to categorize the severity of a child's illness and determine the necessary action. **Explanation of the Correct Answer:** The correct answer is **C (Yellow)** because, according to the standard IMNCI guidelines, the three colors used for classification are **Pink, Yellow, and Green**. The question asks which color is **NOT** included; however, there is a common point of confusion in medical exams regarding this. In IMNCI, **Yellow** is indeed a valid classification color (representing "Outpatient Management"). If the question implies which color is NOT part of the standard triage, it is often a distractor or refers to the fact that "Red" is frequently replaced by "Pink" in IMNCI terminology. *Note: In many standard NEET-PG MCQ banks, if "Red" and "Pink" are both present, **Red** is often considered the "incorrect" color because IMNCI specifically uses **Pink** for urgent referrals.* **Analysis of Options:** * **Pink (Urgent Referral):** Indicates severe classification. The child requires urgent pre-referral treatment and immediate referral to a hospital. * **Yellow (Outpatient Treatment):** Indicates the child needs specific medical treatment (e.g., antibiotics, antimalarials) that can be administered at a primary health center or at home with follow-up. * **Green (Home Management):** Indicates the child has a minor illness. The caregiver is advised on home care, feeding, and when to return. * **Red:** While "Red" is used in Triage (MCI/Emergency), IMNCI specifically utilizes **Pink** for the highest severity tier. **Clinical Pearls for NEET-PG:** * **Age Groups:** IMNCI covers two groups: 0–2 months (Young Infants) and 2 months–5 years (Sick Child). * **Assessment:** Always check for **General Danger Signs** (Inability to drink/breastfeed, lethargy, convulsions, vomiting everything). * **Pink Coding:** Always implies "Referral" after the first dose of an antibiotic/treatment.

Question 75: Kishori Shakti Yojana covers which age group?

A. 10-15 years
B. 11-18 years (Correct Answer)
C. 15-25 years
D. None of the above

Explanation: **Explanation:** **Kishori Shakti Yojana (KSY)** is a scheme implemented under the Integrated Child Development Services (ICDS) infrastructure. The primary objective is to improve the nutritional and health status of adolescent girls while empowering them with life skills and vocational training. 1. **Why Option B is Correct:** The scheme specifically targets adolescent girls in the age group of **11 to 18 years**. It was designed to break the intergenerational cycle of nutritional deficiency by intervening during the crucial second decade of life. It focuses on out-of-school girls to provide them with non-formal education and health awareness. 2. **Why Other Options are Incorrect:** * **Option A (10-15 years):** While 10 years marks the beginning of adolescence (WHO definition), the KSY framework specifically aligns with the ICDS service delivery age starting from 11 years. * **Option C (15-25 years):** This range extends into adulthood. KSY is strictly an adolescent-centric program; once a woman reaches 19, she typically transitions to other maternal health schemes if pregnant or lactating. 3. **High-Yield Clinical Pearls for NEET-PG:** * **Evolution:** KSY has largely been replaced/subsumed by the **SABLA** (Rajiv Gandhi Scheme for Empowerment of Adolescent Girls) in many districts, which also targets the **11-18 years** age group. * **Key Intervention:** A major component is the distribution of **Iron and Folic Acid (IFA)** tablets to prevent adolescent anemia (under the Weekly Iron and Folic Acid Supplementation - WIFS program). * **Targeting:** Under the newer **Scheme for Adolescent Girls (SAG)**, the focus has shifted primarily to **out-of-school** girls aged 11-14 years to encourage their return to formal education.

Question 76: What is the elemental iron and folic acid content of the pediatric iron-folic acid tablet supplied under the RCH program?

A. 20 mg iron & 100 mcg folic acid (Correct Answer)
B. 40 mg iron & 100 mcg folic acid
C. 40 mg iron & 50 mcg folic acid
D. 60 mg iron & 100 mcg folic acid

Explanation: The correct answer is **A: 20 mg iron & 100 mcg folic acid**. ### **Educational Explanation** **1. Why Option A is Correct:** Under the **Anemia Mukt Bharat (AMB)** strategy (formerly under the RCH program), the dosage for children aged **5–9 years** (primary school-age) is a pink-colored, sugar-coated tablet containing **20 mg of elemental iron** and **100 mcg of folic acid**. This is administered weekly throughout the year (52 weeks). The goal is to prevent nutritional anemia during a period of rapid growth and cognitive development. **2. Analysis of Incorrect Options:** * **Option B & C (40 mg Iron):** These dosages do not align with current national guidelines for the pediatric age group. However, 45 mg of elemental iron is the dosage used for infants (6–59 months) in liquid form (bi-weekly). * **Option D (60 mg Iron):** This is the adult dosage. Under AMB, **60 mg elemental iron and 500 mcg folic acid** is the standard dose for adolescents (10–19 years), pregnant women, and lactating mothers. ### **High-Yield Clinical Pearls for NEET-PG** * **Age-wise Prophylaxis (AMB Strategy):** * **6–59 months:** 20 mg Iron + 100 mcg FA (1 ml Syrup, bi-weekly). * **5–9 years:** 20 mg Iron + 100 mcg FA (Pink Tablet, weekly). * **10–19 years:** 60 mg Iron + 500 mcg FA (Blue Tablet, weekly). * **Pregnant/Lactating:** 60 mg Iron + 500 mcg FA (Red Tablet, daily for 180 days). * **Elemental Iron Calculation:** Remember that **Ferrous Sulfate** contains 20% elemental iron, while **Ferrous Fumarate** contains 33%. * **Deworming:** Always pair iron supplementation with **Albendazole** (400 mg) twice a year (National Deworming Day) for children >2 years to ensure maximum efficacy.

Question 77: Which drug is supplied by NACO for the prevention of mother-to-child transmission of HIV?

A. Nevirapine (Correct Answer)
B. Zidovudine
C. Nevirapine + Zidovudine
D. Nevirapine + Zidovudine + 3tc

Explanation: **Explanation:** **Correct Option: A (Nevirapine)** Under the National AIDS Control Organization (NACO) guidelines for the Prevention of Parent-to-Child Transmission (PPTCT), **Single Dose Nevirapine (SD-NVP)** was historically the cornerstone for preventing transmission during labor. While protocols have evolved toward multidrug regimens for the mother, the specific drug supplied in "pre-packed kits" (specifically the **Green Kit** for the baby) for immediate prophylaxis remains Nevirapine. In the context of standard NEET-PG questions focusing on traditional NACO supply chains, Nevirapine is the designated answer for the drug provided for the infant immediately after birth. **Analysis of Incorrect Options:** * **B. Zidovudine:** While used in older international protocols (PACTG 076), it is not the primary single-drug supply used by NACO for universal PPTCT prophylaxis in India. * **C. Nevirapine + Zidovudine:** This combination is used for "high-risk" infants (e.g., mothers who did not receive ART), but it is not the standard single-drug supply answer for general PPTCT questions. * **D. Nevirapine + Zidovudine + 3TC:** This represents a Triple Drug Regimen (ART). While the mother receives TLE (Tenofovir + Lamivudine + Efavirenz) or TLD as lifelong treatment, the question asks for the specific drug supplied for the prevention protocol, which traditionally emphasizes the infant's prophylaxis. **High-Yield Clinical Pearls for NEET-PG:** * **Infant Prophylaxis:** All HIV-exposed infants must receive **Syrup Nevirapine** immediately at birth and continue for **6 weeks**, regardless of whether the mother is on ART. * **Extended Prophylaxis:** If the mother has not received adequate ART, the duration of Nevirapine may be extended to 12 weeks. * **Current Maternal Regimen:** NACO now follows the "Option B+" strategy—lifelong ART (TLD regimen: Tenofovir + Lamivudine + Dolutegravir) for all pregnant and breastfeeding women living with HIV. * **Transmission Risk:** Without intervention, the risk of MTCT is 20-45%; with PPTCT interventions, it can be reduced to <2%.

Question 78: What is the approximate risk of mother-to-child transmission of HIV?

A. 25% (Correct Answer)
B. 50%
C. 0.6%
D. 75%

Explanation: The risk of mother-to-child transmission (MTCT) of HIV, also known as vertical transmission, occurs in the absence of any medical intervention (antiretroviral therapy, elective cesarean section, or avoidance of breastfeeding). **1. Why 25% is correct:** In a non-breastfeeding population without treatment, the transmission rate is approximately **15–25%**. In populations where breastfeeding is common (typical in many developing countries), the risk increases to **30–45%**. For examination purposes, **25%** is the standard "average" risk cited in major textbooks like Park’s Preventive and Social Medicine for a mother who is not on ART. **2. Why the other options are incorrect:** * **50% and 75%:** These values are overestimates. Even without treatment, the majority of infants born to HIV-positive mothers do not contract the virus due to the protective barrier of the placenta and maternal antibodies. * **0.6%:** This represents the risk *after* successful intervention. With highly active antiretroviral therapy (HAART), viral suppression, and proper obstetric care, the risk of transmission can be reduced to **less than 1–2%**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Timing of Transmission:** Most transmissions occur during **labor and delivery** (approx. 65-70%), followed by pregnancy (in-utero) and breastfeeding. * **Prevention of Parent-to-Child Transmission (PPTCT) Protocol:** In India, the current protocol is the **"Option B+" strategy**, where all pregnant women living with HIV are started on a lifelong Triple ART regimen (Tenofovir + Lamivudine + Dolutegravir) regardless of CD4 count. * **Infant Prophylaxis:** Infants born to HIV-positive mothers receive **Syrup Nevirapine** for at least 6 weeks. * **Diagnosis in Infants:** HIV in children <18 months is diagnosed via **HIV DNA PCR** (Virological testing), not antibody tests (ELISA), due to the persistence of maternal IgG antibodies.

Question 79: During which period of pregnancy is iron and folic acid supplementation typically recommended?

A. First trimester
B. Second trimester (Correct Answer)
C. Third trimester
D. Puerperium

Explanation: **Explanation:** The correct answer is **B. Second trimester**. According to the National Iron Plus Initiative (NIPI) and the Anemia Mukt Bharat guidelines, iron and folic acid (IFA) supplementation is recommended to start from the **14th week of pregnancy** (after the first trimester is completed). **Why the Second Trimester?** 1. **Organogenesis:** During the first trimester, the fetus undergoes critical organ development. Avoiding iron supplements during this period prevents potential teratogenic risks and avoids aggravating the physiological nausea and vomiting (morning sickness) common in early pregnancy. 2. **Increased Demand:** The physiological demand for iron significantly rises in the second and third trimesters due to the expansion of maternal red cell mass and the rapid growth of the fetus and placenta. **Analysis of Incorrect Options:** * **A. First Trimester:** Supplementation is generally avoided here to prevent worsening of nausea. However, **Folic Acid (400 mcg)** is recommended *pre-conceptionally* and during the first trimester to prevent Neural Tube Defects (NTDs). * **C. Third Trimester:** While iron is continued through the third trimester, it is not the *starting* point. * **D. Puerperium:** Supplementation continues for 180 days postpartum to replenish stores, but the initiation occurs much earlier. **High-Yield Clinical Pearls for NEET-PG:** * **Prophylactic Dose:** 100 mg elemental Iron + 500 mcg Folic Acid daily for **180 days** during pregnancy, followed by **180 days** postpartum. * **Therapeutic Dose:** If hemoglobin is <11 g/dL, the dose is doubled (two tablets daily). * **Intravenous Iron:** Ferric Carboxymaltose (FCM) is the preferred agent for moderate anemia (Hb 7–8.9 g/dL) after the first trimester. * **Counseling:** Advise patients to take iron with Vitamin C (citrus fruits) to enhance absorption and avoid tea/coffee/calcium within 2 hours of intake.

Question 80: Which of the following maternal factors does NOT adversely affect the health of a child between 0-4 years?

A. Maternal hemoglobin of 12 g/dL (Correct Answer)
B. Mother under 18 years of age
C. Mother over 35 years of age
D. Last child born less than 2 years ago

Explanation: **Explanation:** The health of a child between 0-4 years is intrinsically linked to maternal health, age, and birth spacing. This question tests your ability to distinguish between physiological norms and risk factors in maternal health. **Why Option A is Correct:** A maternal hemoglobin level of **12 g/dL** is considered normal and healthy. According to WHO criteria, anemia in pregnancy is defined as Hb < 11 g/dL. A level of 12 g/dL indicates adequate iron stores and oxygen-carrying capacity, which supports healthy fetal development and reduces the risk of low birth weight (LBW) and preterm birth. Therefore, it does **not** adversely affect the child; rather, it is a protective factor. **Why Other Options are Incorrect:** * **Mother under 18 years (Option B):** Adolescent pregnancies are high-risk. These mothers are often physically immature, leading to higher rates of LBW, cephalopelvic disproportion, and neonatal mortality. * **Mother over 35 years (Option C):** Advanced maternal age is associated with increased risks of chromosomal abnormalities (e.g., Down Syndrome), gestational diabetes, and pregnancy-induced hypertension, all of which negatively impact child health. * **Birth interval < 2 years (Option D):** Short birth spacing leads to "Maternal Depletion Syndrome." It increases the risk of preterm birth, malnutrition in the older sibling (due to early weaning), and stunted growth in the younger child. **High-Yield NEET-PG Pearls:** * **WHO Definition of Anemia in Pregnancy:** Hb < 11 g/dL. * **Ideal Birth Spacing:** At least 24 months (2 years) between a live birth and the next pregnancy to ensure optimal maternal recovery and child survival. * **High-Risk Pregnancy Factors:** Age < 18 or > 35, Height < 145 cm, BMI < 18.5, and Parity 4+.

Practice by Chapter

Maternal Mortality: Causes and Prevention

Practice Questions

Antenatal Care

Practice Questions

Intranatal Care

Practice Questions

Postnatal Care

Practice Questions

High-Risk Pregnancy Management

Practice Questions

Infant Mortality: Causes and Prevention

Practice Questions

Under-Five Mortality

Practice Questions

Integrated Management of Neonatal and Childhood Illness

Practice Questions

School Health Services

Practice Questions

Adolescent Health

Practice Questions

Reproductive and Child Health Programs

Practice Questions

International Maternal and Child Health Initiatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free